Advertisement
Table 1 Patient characteristics
| Characteristics | Total (N = 78) | Non-mCR (N = 37) | mCR (N = 41) | P-value |
|---|---|---|---|---|
| Age, median (range) | 62 (24–79) | 62 (24–76) | 61 (42–79) | 0.288 |
| Sex, n (%) | ||||
| Male | 63 (80.8) | 27 (73.0) | 36 (87.8) | |
| Female | 15 (19.23) | 10 (27.0) | 5 (12.2) | 0.097 |
| ECOG PS, n (%) | ||||
| 0 | 19 (24.4) | 8 (21.6) | 11 (26.8) | |
| 1 | 58 (74.4) | 28 (75.7) | 30 (73.2) | |
| 2 | 1 (1.3) | 1 (2.7) | 0 (0.0) | 0.601* |
| Location, n (%) | ||||
| Oropharynx | 47 (60.3) | 19 (51.4) | 28 (68.3) | |
| Hypopharynx | 19 (24.4) | 11 (29.7) | 8 (19.5) | |
| Larynx | 3 (3.9) | 2 (5.4) | 1 (2.4) | |
| Oral cavity | 5 (6.4) | 4 (10.8) | 1 (2.4) | |
| Nasal cavity/PNS | 1 (1.3) | 0 (0.0) | 1 (2.4) | |
| Others | 3 (3.9) | 1 (2.7) | 2 (4.9) | 0.364* |
| Pathology, n (%) | ||||
| Undifferentiated SCC | 2 (2.6) | 2 (5.4) | 0 (0.0) | |
| Poorly differentiated SCC | 13 (16.7) | 4 (10.8) | 9 (22.0) | |
| Moderately differentiated SCC | 20 (25.6) | 7 (18.9) | 13 (31.7) | |
| Well differentiated SCC | 7 (9.0) | 6 (16.2) | 1 (2.4) | |
| Nonkeratinizing carcinoma | 1 (1.3) | 1 (2.7) | 18 (43.9) | |
| Unknown/not specified SCC | 35 (44.9) | 17 (45.6) | 0 (0.0) | 0.058* |
| TNM Stage, n (%) | ||||
| III | 23 (29.5) | 8 (21.6) | 15 (36.6) | |
| IVA | 54 (69.2) | 29 (78.4) | 25 (61.0) | |
| IVB | 1 (1.3) | 0 (0.0) | 1 (2.4) | 0.140* |
| IC, n (%) | 50 (64.1) | 25 (67.6) | 25 (61.0) | |
| FP | 4 (5.1) | 3 (8.1) | 1 (2.4) | |
| DFP | 16 (20.5) | 6 (16.2) | 10 (24.4) | |
| DP | 26 (33.3) | 14 (37.8) | 12 (29.3) | |
| DP + cetuximab | 4 (5.1) | 2 (5.4) | 2 (4.9) | 0.544 |
| CRT regimen, n (%) | ||||
| Cisplatin | 71 (91.0) | 33 (89.2) | 38 (92.7) | |
| Cetuximab | 3 (3.9) | 1 (2.7) | 2 (4.9) | |
| Cisplatin + cetuximab | 3 (3.9) | 2 (5.4) | 1 (2.4) | |
| Cisplatin + 5-FU | 1 (1.3) | 1 (2.7) | 0 (0.0) | 0.689* |
| Total radiation dose | ||||
| > 60 Gy | 80 (97.6) | 38 (97.4) | 42 (97.7) | |
| ≤ 60 Gy | 2 (2.4) | 1 (2.6) | 1 (2.3) | 1.000* |
| Failure in six months, n (%) | 10 (12.8) | 10 (27.0) | 0 (0.0) | <0.001* |
| Locoregional failure alone | 9 (11.5) | 9 (24.3) | 0 (0.0) | |
| Systemic & locoregional failure | 1 (1.3) | 1 (2.7) | 0 (0.0) | |
| Immediate salvage op, n (%) | 6 (7.7) | 6 (16.2) | 0 (0.0) | 0.009* |
